UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4292-4302

2002

Volltextzugriff (PDF)

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Annals of oncology, 2003-08, Vol.14 (8), p.1227-1233

2003

Volltextzugriff (PDF)

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Annals of oncology, 2009-07, Vol.20 (7), p.1203-1209

2009

Volltextzugriff (PDF)

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM

Annals of oncology, 2012-10, Vol.23 (10), p.2566-2572

2012

Volltextzugriff (PDF)

Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer

British journal of cancer, 2003-11, Vol.89 (10), p.1927-1933

2003

Volltextzugriff (PDF)

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

British journal of cancer, 2013-10, Vol.109 (9), p.2453-2461

2013

Volltextzugriff (PDF)

Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma

The Journal of pathology, 2005-04, Vol.205 (5), p.597-605

2005

Volltextzugriff (PDF)

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

Gynecologic oncology, 2001-12, Vol.83 (3), p.549-554

2001

Volltextzugriff (PDF)

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix

Clinical cancer research, 1997-09, Vol.3 (9), p.1501-1505

1997

Volltextzugriff (PDF)

Persistent Adenovirus-mediated Thymidine Kinase Gene Expression in Ovarian Cancer Cells Increases Cell Killing Efficacy Over Time

Anticancer research, 2008-09, Vol.28 (5A), p.2569-2575

2008

Volltextzugriff (PDF)

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50

Cancer research (Chicago, Ill.), 2000-05, Vol.60 (9), p.2348-2350

2000

Volltextzugriff (PDF)

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy

Gynecologic oncology, 2010-12, Vol.119 (3), p.500-505

2010

Volltextzugriff (PDF)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

British Journal of Cancer, 1999-09, Vol.81 (1), p.179-183

1999

Volltextzugriff (PDF)

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

Breast (Edinburgh), 2009-06, Vol.18 (3), p.159-164

2009

Volltextzugriff (PDF)

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma

British journal of cancer, 1995-03, Vol.71 (3), p.451-455

1995

Volltextzugriff (PDF)

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study

Oncology research and treatment, 2001-06, Vol.24 (3), p.256-260

2001

Volltextzugriff (PDF)

Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion

Cancer research (Chicago, Ill.), 1995-07, Vol.55 (13), p.2743-2745

1995

Volltextzugriff (PDF)

Histologic and immunohistochemical analysis of tissue response to adenovirus‐mediated herpes simplex thymidine kinase gene therapy of ovarian cancer

International journal of gynecological cancer, 2002-01, Vol.12 (1), p.66-73

2002

Volltextzugriff (PDF)

Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison

Anticancer research, 1999-05, Vol.19 (3B), p.2189

1999

Volltextzugriff (PDF)

In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration

Gynecologic oncology, 1996-05, Vol.61 (2), p.175-179

1996

Volltextzugriff (PDF)

Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin

International journal of cancer, 1998-07, Vol.77 (3), p.415-423

1998

Volltextzugriff (PDF)

Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer

Anticancer research, 1999-09, Vol.19 (5C), p.4391

1999

Volltextzugriff (PDF)

p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma

British journal of cancer, 1996-10, Vol.74 (8), p.1157-1160

1996

Volltextzugriff (PDF)

Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro

Urologic oncology, 2003-05, Vol.21 (3), p.197-205

2003

Volltextzugriff (PDF)

Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer

Anticancer research, 1999-05, Vol.19 (3B), p.2365

1999

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM

Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix

Persistent Adenovirus-mediated Thymidine Kinase Gene Expression in Ovarian Cancer Cells Increases Cell Killing Efficacy Over Time

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study

Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion

Histologic and immunohistochemical analysis of tissue response to adenovirus‐mediated herpes simplex thymidine kinase gene therapy of ovarian cancer

Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison

In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration

Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin

Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer

p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma

Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro

Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer

Aktive Filter

Suchergebnisse filtern